Non-TNF biologic beats second anti-TNF in rheumatoid arthritis

Non-TNF biologic beats second anti-TNF in rheumatoid arthritis

(HealthDay)—A non-tumor necrosis factor (TNF)-targeted biologic is more effective than a second anti-TNF drug for treatment of rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug, according to a study published in the Sept. 20 issue of the Journal of the American Medical Association.

Jacques-Eric Gottenberg, M.D., Ph.D., from the Strasbourg University Hospital in France, and colleagues randomized 300 patients with with persistent disease activity and an to anti-TNF therapy to receive a non-TNF-targeted biologic agent or an anti-TNF that differed from their previous treatment. Overall, 89.7 percent of patients completed the study.

The researchers found that 69 percent of patients in the non-TNF group and 52 percent in the second anti-TNF group achieved a good or moderate European League Against Rheumatism response (odds ratio, 2.06). The non-TNF group had a lower disease activity score in 28 joints-erythrocyte sedimentation rate than in the second anti-TNF group (mean difference, −0.43). More patients in the non-TNF group showed low disease activity at weeks 24 and 52 (odds ratio, 2.09 and 2.26, respectively).

"Among patients with rheumatoid arthritis previously treated with anti-TNF drugs but with inadequate primary response, a non-TNF biologic agent was more effective in achieving a good or moderate response at 24 weeks than was the second anti-TNF medication," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further

Researchers uncover new mode of action for HUMIRA in rheumatoid arthritis patients

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Non-TNF biologic beats second anti-TNF in rheumatoid arthritis (2016, September 21) retrieved 19 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors